Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for LONAFARNIB
- Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
- Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
- Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
- A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
- Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
- Titrating-Dose of Lonafarnib in Combination With Ritonavir
- Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
- Lonafarnib With Ritonavir in HDV (LOWR-2)
- Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
- Lonafarnib for Chronic Hepatitis D
- Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
- A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
- Lonafarnib in Metastatic Breast Cancer
- A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
- Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
- Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
- Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer
- Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
- 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
- Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide
- 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
- Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
- Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
- Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
- Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
- Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
- Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
- SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
- SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
- SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
- SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
- Combination Chemotherapy in Treating Patients With Advanced Cancer
Clinical trials list
click for details